Equus Caballus Skin

Dosage for Equus Caballus Skin is highly individualized and must be determined by an allergist or immunologist based on the patient's sensitivity levels. There is no 'standard' dose that applies to all patients.

Diagnostic Dosing

• Skin Prick Test (SPT): Typically uses a concentrated glycerinated extract (e.g., 1:10 or 1:20 w/v). A single drop is applied to the skin, and a lancet is used to prick the epidermis.
• Intradermal Test: If the SPT is negative but clinical suspicion remains high, a more dilute aqueous extract (e.g., 1:1000 or 1:500 w/v) is injected into the dermis to create a small bleb.

Immunotherapy Dosing (SCIT)

Immunotherapy is divided into two distinct phases:

1. 1Build-up Phase: Patients receive injections once or twice weekly. The starting dose is usually 1,000 to 10,000 times more dilute than the eventual maintenance dose. The concentration is gradually increased over 3 to 6 months.
2. 2Maintenance Phase: Once the 'top dose' is reached (the highest dose the patient can tolerate without a significant local or systemic reaction), the interval between injections is increased to every 2 to 4 weeks. This phase typically lasts 3 to 5 years.

Equus Caballus Skin is approved for use in children, provided they are old enough to cooperate with the testing and injection procedure.

• Dosing: The dosing schedule for children is generally the same as for adults, as the immune response is not strictly weight-dependent. However, clinicians may use a more cautious build-up phase in very young children (e.g., under age 5) due to the difficulty of communicating early symptoms of a systemic reaction.
• Safety: Clinical studies have shown that immunotherapy is effective in the pediatric population and may even prevent the development of asthma in children with allergic rhinitis (the 'allergic march').

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the allergenic proteins are not cleared in a way that would lead to toxic accumulation. However, patients with severe renal disease may have altered immune responses.

Hepatic Impairment

No dosage adjustments are needed for hepatic impairment.

Elderly Patients

Caution is advised in elderly patients, particularly those with underlying cardiovascular disease. The primary risk is not the extract itself, but the patient's ability to tolerate a systemic reaction or the administration of epinephrine if a reaction occurs.

Equus Caballus Skin extract is never self-administered. It must be administered by a healthcare professional in a medical facility.

• Administration: The injection is given subcutaneously (just under the skin) in the posterior aspect of the upper arm.
• Observation: Patients MUST remain in the doctor's office for at least 30 minutes following every injection to monitor for signs of anaphylaxis.
• Storage: Extracts must be kept refrigerated at 2°C to 8°C (36°F to 46°F). Freezing or exposure to high heat will denature the proteins and render the extract ineffective or dangerous.

If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated to ensure safety. If a dose is missed during the maintenance phase for more than a few weeks, the allergist will typically step back the concentration to avoid a systemic reaction when resuming.

An 'overdose' in the context of Equus Caballus Skin usually refers to an injection given at a concentration higher than the patient's current tolerance level.

• Signs: Rapid onset of hives, swelling of the throat, wheezing, drop in blood pressure, or abdominal cramping.
• Emergency Measures: Immediate administration of intramuscular epinephrine (0.3mg for adults), followed by antihistamines, corticosteroids, and potentially IV fluids or oxygen. Emergency medical services (911) should be summoned if the reaction occurs outside a hospital setting.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Always inform your provider of any new medications or health changes before your next injection.

Most patients undergoing treatment with Equus Caballus Skin extract will experience some form of local reaction. These are generally considered part of the body's normal response to the allergen.

• Local Swelling and Redness: A 'wheal' or 'hive' at the site of the injection. This typically appears within 20 minutes and may last for several hours. It may feel itchy or warm to the touch.
• Delayed Local Reaction: Swelling that appears 6 to 24 hours after the injection. While uncomfortable, these are usually not dangerous and can be managed with cold compresses or over-the-counter antihistamines.
• Itching (Pruritus): General itching at the injection site is very common.

• Large Local Reactions: Swelling that exceeds 5-10 centimeters in diameter. While not life-threatening, these often require a dosage adjustment for the next injection.
• Fatigue: Some patients report feeling unusually tired for a few hours following their immunotherapy session.
• Mild Nasal Congestion: A slight increase in 'hay fever' symptoms shortly after the injection.

• Generalized Urticaria (Hives): Hives appearing on parts of the body far from the injection site. This is a sign of a systemic reaction and requires immediate medical attention.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.
• Vasovagal Syncope: Fainting or lightheadedness due to the needle stick rather than the extract itself.

> Warning: Stop receiving Equus Caballus Skin injections and call your doctor immediately or seek emergency care if you experience any of the following symptoms of anaphylaxis:

• Respiratory Distress: Difficulty breathing, wheezing, or a persistent cough.
• Throat Tightness: A feeling that the throat is closing or difficulty swallowing (laryngeal edema).
• Cardiovascular Collapse: A sudden drop in blood pressure, feeling faint, or a rapid/weak pulse.
• Gastrointestinal Distress: Severe nausea, vomiting, or abdominal cramping that occurs rapidly after an injection.
• Cyanosis: Bluish tint to the lips or fingernails, indicating a lack of oxygen.

There are no known long-term 'toxic' effects of Equus Caballus Skin extract. Unlike many medications, it does not damage the liver, kidneys, or heart over time. The primary long-term effect is the desired modulation of the immune system. However, if a patient develops an autoimmune condition, the role of ongoing immunotherapy should be re-evaluated by a specialist.

Allergenic extracts, including Equus Caballus Skin, carry a FDA Black Box Warning regarding the risk of severe systemic reactions.

Summary of Warning:

• This product can cause severe, life-threatening systemic reactions, including anaphylaxis.
• It should only be administered by healthcare professionals experienced in the treatment of anaphylaxis and in a facility equipped with emergency supplies (epinephrine, oxygen, IV fluids).
• Patients with unstable asthma are at a significantly higher risk for fatal reactions.
• Patients taking beta-blockers may be resistant to the effects of epinephrine used to treat a reaction.
• A 30-minute post-injection observation period is mandatory.

Report any unusual symptoms to your healthcare provider. Even a 'small' increase in local swelling should be reported before your next dose, as it may predict a future systemic reaction.

Equus Caballus Skin extract is a potent biological agent. Its use requires strict adherence to safety protocols to minimize the risk of life-threatening allergic reactions. Patients must be 'clinically stable' on the day of their injection. This means no active asthma flare-ups, no fever, and no significant new illness.

No FDA black box warnings for Equus Caballus Skin? No, this is incorrect. As noted in the side effects section, there is a mandatory Black Box Warning for all injectable allergenic extracts. The primary focus of this warning is the risk of anaphylaxis and the requirement for administration in a controlled medical environment with a minimum 30-minute observation period. The warning also highlights that patients with severe or poorly controlled asthma are at the highest risk for death following an immunotherapy injection.

• Anaphylaxis Risk: This is the primary concern. Anaphylaxis can occur even in patients who have tolerated previous injections without issue. Factors that can increase this risk on a given day include exercise shortly after the injection, hot showers, or being in the midst of a heavy allergy season.
• Asthma Status: Before every injection, the healthcare provider should assess the patient's asthma. If the patient's Peak Expiratory Flow (PEF) is significantly below their personal best, the injection should be deferred.
• Injection Technique: Accidental intravenous injection of the extract can cause immediate, severe anaphylaxis. The provider must aspirate the syringe to ensure the needle is not in a blood vessel before injecting.
• Beta-Blocker Use: Patients taking beta-blockers (for high blood pressure or heart issues) are at increased risk because these drugs block the action of epinephrine, making it difficult to treat a reaction if one occurs.

Unlike many drugs, Equus Caballus Skin does not require routine blood work (like liver or kidney tests). Monitoring is clinical:

• Immediate Observation: 30 minutes of sitting in the waiting room after every shot.
• Local Reaction Log: Patients are often asked to record the size of any swelling that occurs at home later that evening.
• Spirometry: Periodic lung function tests may be required for patients with asthma to ensure they remain candidates for immunotherapy.

Generally, Equus Caballus Skin does not affect the ability to drive. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive until cleared by a physician. Some patients feel 'foggy' or tired after a shot and should use caution until they know how they react.

Alcohol consumption should be avoided for several hours before and after an injection. Alcohol can cause vasodilation (widening of blood vessels), which may increase the rate of allergen absorption and potentially trigger a more severe reaction.

Immunotherapy is typically discontinued after 3 to 5 years of successful maintenance. There is no 'withdrawal syndrome' associated with stopping Equus Caballus Skin. However, if stopped prematurely (e.g., after only 1 year), the allergic symptoms are likely to return quickly. Tapering is not required for the drug itself, but the clinical decision to stop should be made based on the patient's symptom control.

> Important: Discuss all your medical conditions with your healthcare provider before starting Equus Caballus Skin. Ensure they have a complete list of your other medications, especially heart or blood pressure drugs.

There are few absolute contraindications for drug combinations, but the following are of extreme concern:

• Beta-Blockers (Non-selective and Selective): While not strictly contraindicated in all cases, many allergists will not perform immunotherapy on patients taking beta-blockers (e.g., propranolol, metoprolol, atenolol). The clinical consequence is that if the patient has anaphylaxis, the beta-blocker prevents epinephrine from working, which can lead to death.

• ACE Inhibitors: Drugs like lisinopril or enalapril may increase the risk of more severe systemic reactions or interfere with the body's natural compensatory mechanisms during an allergic reaction.
• MAO Inhibitors (MAOIs): Used for depression, these can potentiate the effects of epinephrine if it needs to be administered, leading to a dangerous spike in blood pressure.
• Tricyclic Antidepressants: Similar to MAOIs, these can interfere with the metabolism of emergency medications used to treat reactions.

• Antihistamines: While not dangerous, taking a high-dose antihistamine before a diagnostic skin test will cause a false-negative result. Patients must typically stop antihistamines (e.g., cetirizine, loratadine, diphenhydramine) for 3 to 7 days before testing.
• Systemic Corticosteroids: Long-term use of high-dose prednisone may suppress the immune response to the extract, potentially reducing the efficacy of the immunotherapy.

• Alcohol: As mentioned previously, alcohol can increase the risk of a systemic reaction by increasing blood flow and allergen absorption.
• Large Meals: There is some anecdotal evidence that very large, heavy meals immediately before an injection might slightly alter the rate of absorption, though this is not a standard restriction.

• St. John's Wort: May theoretically affect the metabolism of medications used to treat allergic reactions, though the clinical significance is low.
• Ginkgo Biloba: Known for its anti-platelet effects, it should be used with caution as it might theoretically affect the vascular response during a reaction.

• Skin Testing: Equus Caballus Skin extract is itself used for a 'lab test' (skin prick). Any drug that suppresses the skin's histamine response (antihistamines, certain antidepressants like amitriptyline) will interfere with the results.
• Total IgE and Specific IgE: Immunotherapy will eventually cause changes in these blood tests (often a temporary rise in sIgE followed by a long-term decline), which the clinician must interpret in the context of the treatment.

Interaction Mechanism Summary

Most interactions with Equus Caballus Skin are pharmacodynamic rather than pharmacokinetic. They do not change the level of the horse proteins in the blood; instead, they change how the body responds to those proteins or how the body responds to the emergency drugs (like epinephrine) used to treat side effects.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including eye drops and topical creams, as these can sometimes contain beta-blockers or other interacting substances.

Equus Caballus Skin extract must NEVER be used in the following circumstances:

• Severe, Uncontrolled Asthma: Patients with a FEV1 (Forced Expiratory Volume) consistently below 70% of predicted values are at an unacceptably high risk for a fatal reaction to immunotherapy.
• Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months. The stress of a potential systemic reaction and the subsequent need for epinephrine could be fatal to a compromised heart.
• History of Severe Anaphylaxis to this Specific Extract: If a patient has had a near-fatal reaction to horse extract in the past, the risks of continuing immunotherapy usually outweigh the benefits.
• Hypersensitivity to Excipients: Patients with a known, documented severe allergy to phenol (the preservative used in most extracts) or glycerin should not receive these injections.

In these cases, the healthcare provider will perform a careful risk-benefit analysis:

• Autoimmune Diseases: There is a theoretical concern that stimulating the immune system with extracts could worsen conditions like Lupus or Rheumatoid Arthritis, though data is conflicting.
• Malignancy: Patients currently undergoing chemotherapy or with active cancer may have unpredictable immune responses.
• Eosinophilic Esophagitis (EoE): Some evidence suggests that subcutaneous immunotherapy might trigger or worsen EoE in susceptible individuals.
• Young Children (Under age 5): Not strictly contraindicated, but the risk is higher because they cannot communicate early symptoms of a reaction.

Patients allergic to horses often show cross-reactivity with other members of the Equidae family, such as donkeys and mules. There is also a known clinical syndrome called the Pork-Cat Syndrome, but more relevantly, some patients allergic to horse dander may react to horse meat or even certain mammalian serums due to cross-reacting albumin proteins (Equ c 3).

> Important: Your healthcare provider will evaluate your complete medical history, including your lung function and heart health, before prescribing Equus Caballus Skin.

FDA Pregnancy Category: C

• Risk Summary: There are no adequate and well-controlled studies of Equus Caballus Skin extract in pregnant women. However, the general consensus in the allergy community (supported by the AAAAI and ACAAI) is that immunotherapy should not be started during pregnancy because of the risk of anaphylaxis, which can cause fetal hypoxia (lack of oxygen to the baby).
• Continuing Treatment: If a woman is already on a stable maintenance dose and becomes pregnant, the treatment is usually continued at that dose (without further increases) because the risk of a reaction is low and the benefit of controlling asthma/allergies is high.

Equus Caballus Skin extract is composed of large proteins that are not expected to pass into breast milk in any significant or bioactive quantity. Breastfeeding is generally considered safe for women receiving immunotherapy. There are no known adverse effects on the nursing infant.

• Approved Use: Immunotherapy is highly effective in children and is often recommended to prevent the progression of the 'allergic march' (the transition from eczema to hay fever to asthma).
• Dosing: As noted, the dose is the same as for adults, but the build-up may be slower.
• Growth Effects: There is no evidence that allergenic extracts affect growth or development in children.

• Cardiovascular Risk: The primary concern in patients over 65 is the presence of underlying heart disease. If an elderly patient requires epinephrine for a reaction, it can trigger an arrhythmia or heart attack.
• Polypharmacy: Older patients are more likely to be on beta-blockers or ACE inhibitors, which complicates the safety profile of Equus Caballus Skin.

There are no specific guidelines for renal impairment. The proteins in the extract are broken down by proteases throughout the body and do not rely on renal clearance for their therapeutic effect. However, patients on dialysis should be monitored closely for fluid balance if they experience a systemic reaction.

No dosage adjustments are required. The liver is not the primary site of metabolism for these allergenic proteins.

> Important: Special populations require individualized medical assessment. Always inform your allergist if you become pregnant or are planning to start a family while on immunotherapy.

Equus Caballus Skin extract works by inducing immunological tolerance. The major allergen, Equ c 1, is captured by dendritic cells (antigen-presenting cells) and presented to T-cells. In an allergic individual, this presentation leads to the activation of Th2 cells. Immunotherapy changes this environment. By providing a constant, increasing stimulus, the treatment promotes the development of T-regulatory (Treg) cells. These cells secrete IL-10, which has several effects:

1. 1It inhibits the production of IgE by B-cells.
2. 2It induces B-cells to switch to the production of IgG4, a non-inflammatory antibody.
3. 3It reduces the recruitment of eosinophils and mast cells to the 'shock organs' (nose, lungs, eyes).

• Dose-Response: There is a clear dose-response relationship in immunotherapy. Low doses are generally ineffective, while higher maintenance doses provide long-term relief.
• Time to Onset: Diagnostic effects (skin test) are seen in 15-20 minutes. Therapeutic effects (symptom relief) usually take 6 to 12 months of treatment to become noticeable.
• Duration of Effect: If a full 3-5 year course is completed, the 'desensitization' can last for many years, or even a lifetime, after the injections are stopped.

| Parameter | Value |

|---|---|

| Bioavailability | Low (Subcutaneous absorption is slow and localized) |

| Protein Binding | N/A (Interacts with IgE/IgG antibodies) |

| Half-life | Proteins: Hours; Immunological Effect: Years |

| Tmax | 15-30 minutes for local histamine release |

| Metabolism | Proteolytic cleavage by local tissue enzymes |

| Excretion | Renal (as small peptide fragments) |

• Composition: A complex mixture of proteins (including Equ c 1, Equ c 2, Equ c 3, and horse serum albumin).
• Solubility: Highly soluble in aqueous buffers and 50% glycerin solutions.
• Molecular Weight: Ranges from 17 kDa (Equ c 1) to 67 kDa (Horse Serum Albumin).

Equus Caballus Skin is classified as a Biological: Allergenic Extract. It is grouped with other animal dander extracts (Cat, Dog) and differs from pollen extracts (Grass, Ragweed) in its protein structure and environmental stability.